Angie Inyoung Kim

This inventor holds 12 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 4 EPO patents. Top assignees: Exelixis, Inc., Other. Active years: 2009-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Angie Inyoung Kim. Retrieved from https://idiyas.com/inventor/angie-inyoung-kim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 5)

% Patents Active = 66.7

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 13.5

ph-index = 5

Forward Citations = 98(Granted Patents)

Company Filing History:

11 out of 177

Exelixis, Inc.

patents

1 out of 834,513

Other

patents

Years Active: 2009-2023

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11597699 - MEK inhibitors and methods of their use (2023-03-07),

2. 8697737 - Raf modulators and methods of use (2014-04-15),

3. 8648066 - Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture (2014-02-11),

4. 8637499 - Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture (2014-01-28),

5. 8372851 - Pyrazolo pyrimidines as casein kinase II (CK2) modulators (2013-02-12),

6. 8362002 - Azetidines as MEK inhibitors for the treatment of proliferative diseases (2013-01-29),

7. 8012956 - Tropane compounds (2011-09-06),

8. 7915250 - Azetidines as MEK inhibitors for the treatment of proliferative diseases (2011-03-29),

9. 7872014 - Anaplastic lymphoma kinase modulators and methods of use (2011-01-18),

10. 7846959 - Raf modulators and methods of use (2010-12-07),

11. 7803839 - Azetidines as MEK inhibitors for the treatment of proliferative diseases (2010-09-28),

12. 7576074 - Receptor-type kinase modulators and methods of use (2009-08-18),

Title: Innovations by Angie Inyoung Kim: Pioneering MEK Inhibitors and Raf Modulators

Introduction

Angie Inyoung Kim is a prolific inventor based in San Mateo, California, recognized for her significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 12 patents, she has made noteworthy advancements in the treatment of various proliferative diseases, particularly cancer.

Latest Patents

Among her latest patents, Angie has developed innovative MEK inhibitors. These compounds are defined by a specific formula that includes pharmaceutically acceptable salts and solvates, demonstrating potential in treating proliferative diseases, including cancer. In addition, she has worked on Raf modulators, which are designed to inhibit and modulate protein kinase enzymatic activity. This invention aids in regulating cellular processes such as proliferation and differentiation, which are crucial in managing kinase-dependent diseases.

Career Highlights

Throughout her career, Angie has been associated with prominent companies such as Exelixis, Inc. Her expertise in pharmaceutical development has positioned her at the forefront of innovation in cancer treatment methodologies. Her patented inventions are a testament to her dedication and knowledge in the biomedical field.

Collaborations

Angie Inyoung Kim has collaborated with various professionals, including notable coworkers Joerg Bussenius and Csaba J. Peto. These collaborations have contributed to her success in advancing the understanding and treatment of complex diseases.

Conclusion

Angie Inyoung Kim's innovative work continues to pave the way for new therapeutic options in the battle against cancer. With her extensive patent portfolio and dedication to scientific advancement, she remains a key figure in the realm of pharmaceutical innovations.

Profile summary based on public USPTO records.